Literature DB >> 29974558

Maternal and perinatal complications in pregnant women with urinary tract infection caused by Escherichia coli.

José G Dautt-Leyva1, Adrian Canizalez-Román2,3, Luis F Acosta Alfaro4, Fernando Gonzalez-Ibarra5, Joel Murillo-Llanes3.   

Abstract

AIM: The incidence of urinary tract infection (UTI) in pregnant women may vary from 5-10% and depends on parity, race, socioeconomic status and anatomical and functional changes in pregnancy. In Mexico, preterm birth accounts for 75% of perinatal deaths and 50% of the neurological sequelae attributable directly to prematurity. The objective of the present study is to describe maternal and perinatal complications in pregnant women with UTI caused by Escherichia coli and to find out the antimicrobial susceptibility pattern.
METHODS: A descriptive and longitudinal study of pregnant women admitted to the Women's Hospital in Culiacan, Sinaloa, Mexico, was carried out from January 2013 to December 2014. Patients with E. coli infection were included, and infections caused by other microorganisms were excluded. The sociodemographic variables, causes of hospitalization and the type of maternal and perinatal complications were determined.
RESULTS: The causes of admission to the hospital were threatened preterm labor, and fever and threatened abortion. Of 38 patients with threatened preterm labor, 33 went on to delivery, four were preterm births and two were neonatal deaths. E. coli was sensitive to over 90% of piperacillin-tazobactam, amikacin, nitrofurantoin and carbapenems.
CONCLUSION: According to this study in a Mexican population, the number one admission diagnosis in women with UTI due to E. coli was threatened preterm labor, and fever and threatened abortion. E. coli was sensitive to more than 90% of piperacillin-tazobactam, amikacin, nitrofurantoin and carbapenems.
© 2018 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  zzm321990Escherichia coli; antimicrobial resistance; perinatal complications; urinary tract infection

Mesh:

Year:  2018        PMID: 29974558     DOI: 10.1111/jog.13687

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  5 in total

1.  Culture Requests and Multi-Drug Resistance among Suspected Urinary Tract Infections in Two Tertiary Hospitals in Freetown, Sierra Leone (2017-21): A Cross-Sectional Study.

Authors:  Julian S O Campbell; Saskia van Henten; Zikan Koroma; Ibrahim Franklyn Kamara; Gladys N Kamara; Hemant Deepak Shewade; Anthony D Harries
Journal:  Int J Environ Res Public Health       Date:  2022-04-16       Impact factor: 4.614

2.  Prolactin decreases LPS-induced inflammatory cytokines by inhibiting TLR-4/NFκB signaling in the human placenta.

Authors:  A Olmos-Ortiz; M Déciga-García; E Preciado-Martínez; L Bermejo-Martínez; P Flores-Espinosa; I Mancilla-Herrera; C Irles; A C Helguera-Repetto; B Quesada-Reyna; V Goffin; L Díaz; V Zaga-Clavellina
Journal:  Mol Hum Reprod       Date:  2019-10-28       Impact factor: 4.025

Review 3.  Sacral Neuromodulation in Pregnant Women-A Case Report and Literature Review.

Authors:  Jacek K Szymański; Aneta Słabuszewska-Jóźwiak; Grzegorz Jakiel
Journal:  Int J Environ Res Public Health       Date:  2022-07-08       Impact factor: 4.614

Review 4.  Periodontal Pathogens and Preterm Birth: Current Knowledge and Further Interventions.

Authors:  Milan Terzic; Gulzhanat Aimagambetova; Sanja Terzic; Milena Radunovic; Gauri Bapayeva; Antonio Simone Laganà
Journal:  Pathogens       Date:  2021-06-09

5.  Compartmentalized Innate Immune Response of Human Fetal Membranes against Escherichia coli Choriodecidual Infection.

Authors:  Andrea Olmos-Ortiz; Mayra Hernández-Pérez; Pilar Flores-Espinosa; Gabriela Sedano; Addy Cecilia Helguera-Repetto; Óscar Villavicencio-Carrisoza; María Yolotzin Valdespino-Vazquez; Arturo Flores-Pliego; Claudine Irles; Bruno Rivas-Santiago; Elsa Romelia Moreno-Verduzco; Lorenza Díaz; Verónica Zaga-Clavellina
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.